Studies have shown (37) that 10%-15% of COVID-19 patients have circulating autoantibodies, such as anti-type I interferon autoantibodies, antinuclear antibodies, lupus anticoagulant, anti-SSA/Ro antibodies (38), anticardiolipin antibodies (39), anti-IFN antibodies (40), dermatomyositis-associated anti-MDA5 antibodies, and anti-angiotensin converting enzyme 2 (ACE2) autoantibodies. The gene discussed is CALR; the disease is dermatomyositis.